Diffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | DelveInsight

Diffuse Large B-cell Lymphoma Market Report Summary Diffuse Large B-cell Lymphoma Market Report Summary Discover more about the diffuse large B-cell lymphoma treatment market @Diffuse Large B-cell Lymphoma Medication   Key Factors Driving the Growth of Diffuse Large B-cell Lymphoma Market  Increasing DLBCL Incidence and Aging Population Global DLBCL incidence exceeds150,000cases annually, driven by aging populations (9% aged 65+). In the 7MM, incident cases are...

Diffuse Large B-cell Lymphoma Market Report Summary

Discover more about the diffuse large B-cell lymphoma treatment market @ Diffuse Large B-cell Lymphoma Medication 

Key Factors Driving the Growth of Diffuse Large B-cell Lymphoma Market 

Increasing DLBCL Incidence and Aging Population

Global DLBCL incidence exceeds 150,000 cases annually, driven by aging populations (9% aged 65+). In the 7MM, incident cases are projected to reach ~87K by 2034.

Launch of Emerging Targeted DLBCL Therapies and Immunotherapies

The introduction of novel treatment options, such as CAR-T therapies (Allogene Therapeutics's Cemacabtagene ansegedleucel, Miltenyi Biomedicine's Zamtocabtagene autoleucel, Galapagos's GLPG5101, Novartis' Rapcabtagene Autoleucel, Lyell/ImmPACT Bio's IMPT-314, and others), monoclonal antibodies (Genmab's GEN3014), and bispecific antibodies (Roche/Biogen's LUNSUMIO, AstraZeneca's AZD0486, and others), is expected to propel the DLBCL treatment market.

Growing Investment in R&D and DLBCL Clinical Trials

More than 30 pharmaceutical diffuse large B-cell lymphoma companies, including Roche (Genentech), Biogen, AstraZeneca, Merck, Allogene Therapeutics, Novartis, Pfizer, 2seventy bio, Regeneron Pharmaceuticals, BeiGene, Bristol-Myers Squibb, Otsuka Pharmaceutical, Gilead Sciences, Amgen, and others, are investing heavily in developing next-generation DLBCL therapies, resulting in a stronger pipeline and more approvals.

Improved DLBCL Diagnostic Capabilities and Early Detection

Improved diagnostic tools, such as PET-CT and next-generation sequencing, have boosted early detection rates in DLBCL by nearly 20%, enabling risk stratification and personalized treatment approaches. Early-stage diagnosis now accounts for approximately 35–40% of identified cases, resulting in significantly improved survival outcomes.

Diffuse Large B-cell Lymphoma Treatment Market Analysis

The diffuse large B-cell lymphoma (DLBCL) treatment landscape is witnessing significant growth, driven by the evolving therapeutic options and advancements in targeted therapies. The R-CHOP regimen, comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, continues to serve as the standard first-line therapy, particularly for newly diagnosed patients. However, patients with high-risk disease profiles are increasingly receiving more intensive or combination strategies, such as R-CHOP with agents like lenalidomide or bortezomib, which is expanding treatment adoption and driving market growth.

For indolent lymphomas, management strategies range from watchful waiting to radiotherapy or chemotherapy, while aggressive lymphomas demand intensive chemotherapy protocols often supplemented with prophylactic measures to prevent central nervous system (CNS) involvement. The emphasis on multidisciplinary care and supportive therapies to mitigate side effects is further enhancing patient outcomes and influencing market uptake.

The relapsed and refractory DLBCL segment is particularly propelling market expansion, fueled by the introduction of innovative CD19-directed CAR-T therapies. FDA-approved therapies such as YESCARTA and BREYANZI, available since 2022, have rapidly become preferred options for early-relapsed, high-risk patients, highlighting a shift toward precision medicine. Similarly, KYMRIAH, approved for adult patients with relapsed or refractory large B-cell lymphoma (including DLBCL, high-grade B-cell lymphoma, and DLBCL transformed from follicular lymphoma), is contributing to market momentum, although it is not indicated for primary CNS lymphoma.

The growing adoption of these CAR-T cell therapies, coupled with expanding indications and continued R&D investment in next-generation immunotherapies, is expected to further accelerate the DLBCL treatment market. As patient access improves and therapeutic outcomes continue to advance, the market is poised for sustained growth, underscoring the transformative impact of targeted and personalized therapies in hematologic oncology.

To know more about FDA-approved drugs for diffuse large B-cell lymphoma, visit @ Diffuse Large B-cell Lymphoma Treatment

Diffuse Large B-cell Lymphoma Competitive Landscape

DelveInsight's analysts conclude that there are approximately 30 companies working. Some of the drugs in the DLBCL pipeline include Zamtocabtagene Autoleucel (MB-CART2019.1) (Miltenyi Biomedicine), AZD0486 (AstraZeneca), Maveropepimut-S (BioVaxys/ImmunoVaccine Technologies), Cemacabtagene ansegedleucel (cema-cel) (Allogene Therapeutics), IMPT-314 (Lyell/ImmPACT Bio), and others. 

Miltenyi Biomedicine is advancing a CAR T-cell therapy aimed at treating adult patients with relapsed or refractory diffuse large B-cell lymphoma who have undergone at least one prior line of therapy. Zamtocabtagene autoleucel (Zamto-Cel) is distinctive in its dual targeting of CD19 and CD20 proteins on B cells. 

This investigational therapy has been recognized under the European Union's Priority Medicines (PRIME) scheme for its potential. In August 2020, Miltenyi Biomedicine received Orphan Drug Designation (ODD) from the European Commission for MB-CART2019.1 for the treatment of DLBCL. Interim results from the Phase II DALY II USA trial of Zamto-Cel in patients with relapsed or refractory DLBCL were presented by Miltenyi Biomedicine in December 2024.

AZD0486 is an innovative IgG4, fully human CD19 x CD3 bispecific T-cell engager (TCE), designed with low-affinity binding to CD3 to minimize cytokine release while maintaining potent T-cell-mediated cytotoxicity against cancerous B cells. The therapy showed activity and was well tolerated in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, including those with DLBCL.

The anticipated launch of these emerging DLBCL therapies are poised to transform the diffuse large B-cell lymphoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the diffuse large B-cell lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about diffuse large B-cell lymphoma drugs in development @ Diffuse Large B-cell Lymphoma Clinical Trials 

Recent Developments in the Diffuse Large B-cell Lymphoma Market

Diffuse Large B-cell Lymphoma Epidemiology Segmentation

The latest report provides comprehensive insights into the DLBCL patient pool, incident cases, and how the DLBCL patient population is going to increase by 2034. The analysts report that the incident cases are projected to reach ~87K by 2034 in the 7MM. The diffuse large B-cell lymphoma epidemiology section provides insights into the historical and current diffuse large B-cell lymphoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The diffuse large B-cell lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:

Scope of the Diffuse Large B-cell Lymphoma Market Report

Download the report to understand the diffuse large B-cell lymphoma market trends @ Diffuse Large B-cell Lymphoma Market Report

Table of Contents

Related Reports

Diffuse Large B-cell Lymphoma Clinical Trial Analysis

Diffuse Large B-cell Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DLBCL companies, including Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, among others.

Non-Hodgkin's Lymphoma Market

Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including AbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others.

Non-Hodgkin's Lymphoma Pipeline

Non-Hodgkin's Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NHL companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., among others.

Follicular Lymphoma Market

Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key follicular lymphoma companies, including Merck Sharp and Dohme, AstraZeneca, CRISPR Therapeutics, BeiGene, Nektar Therapeutics, NovalGen, Carna Biosciences, Allogene Therapeutics, Xynomic Pharmaceuticals, Bristol-Myers Squibb, Incyte Corporation, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/diffuse-large-b-cell-lymphoma-market-to-grow-at-a-cagr-of-13-by-2034-in-leading-markets-us-eu4-uk-and-japan--delveinsight-302539882.html